Philips Drives Digital Innovation with Vereos at Society of Nuclear Medicine and Molecular Imaging Annual Meeting

ST. LOUIS, June 9, 2014-- Royal Philips (NYSE: PHG AEX: PHIA) today introduced Vereos PET/CT, the first digital PET/CT scanner, at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging  (SNMMI), taking place this week in St. Louis, Mo.  In addition to Vereos, Philips will showcase a selection of innovative, molecular imaging solutions designed to deliver outstanding image quality, critical clinical information and greater connectivity.

Philips Vereos PET/CT uses innovative digital silicon photomultiplier detectors instead of traditional analog detectors, creating a step change in performance that includes approximately two-times increase in sensitivity gain, volumetric resolution and quantitative accuracy compared to analog systems.* These improvements can ultimately be translated into high image quality, increased diagnostic confidence, improved treatment planning and faster workflows.

"From connected devices to data-driven insights, the pace of imaging innovation is allowing us to see more," said Gene Saragnese, chief executive officer, Imaging Systems, Philips. "Molecular imaging technology is leading the way with digital detection and advanced visualization built on insights from those at the heart of care."

Visitors to the Philips Booth (#1521) at SNMMI will have the opportunity to interact with Vereos digital PET/CT clinical images and technology using engaging 3D visualization tools. This unique experience provides clinicians an understanding of how Vereos can be used to deliver customized care to meet their most pressing needs.

During the SNMMI annual meeting, Philips will also host a series of three "Innovation Talks" in its booth theater area on Monday, June 9. These sessions will spotlight customers, scientists and industry thought leaders who will discuss topics related to the current and future landscape for digital PET, patient-centered imaging, and the importance of creating customized workflows to help manage patient care and radiation dose. Each of the "Innovation Talks" sessions will last 15 minutes and is open to all event attendees.

In addition to Vereos, Philips will showcase a selection of its advanced molecular imaging technology solutions that help contribute to a 360-degree view of the patient and offer increased diagnostic confidence. Designed to provide access to the right data at the right time, these solutions seamlessly exchange health information data, and interpret the data that matters most to help improve patient outcomes and save lives.

These technologies include:

    iPatient: An advanced platform with an intuitive interface, iPatient helps to facilitate patient-centered imaging, allows for efficient communication between the CT system and injector, and aids in the delivery of appropriate contrast dose and consistent image quality.
    BrightView XCT: A SPECT/CT system designed entirely for nuclear medicine, BrightView XCT enables low patient dose levels, high-resolution localization and high-quality attenuation correction, for smart assessments and short exams with the patient's comfort in mind.
    IntelliSpace Portal: Part of Philips' family of clinical information systems within Philips Healthcare Informatics Solutions and Services Group, the IntelliSpace Portal offers extensive clinical coverage, streamlined workflow and continuous evolution of advanced visualization and analysis capabilities within a single solution.

For more information on Philips' presence at SNMMI (Booth #1521), and the full suite of Philips molecular imaging technology solutions, visit www.philips.com/snmmi and follow the #SNMMI14 conversation with @philipshealth.

*GEMINI TF 16

About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 112,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

RELATED LINKS
http://www.usa.philips.com

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.